Suggested remit: To appraise the clinical and cost effectiveness of pegunigalsidase alfa within its marketing authorisation for treating Fabry disease.
Status In progress
Technology type Medicine
Decision Selected
Process STA
ID number 3904

Project Team

Project lead Michelle Adhemar

Email enquiries


Key events during the development of the guidance:

Date Update
10 May 2022 (14:00) Scoping workshop
18 March 2022 - 20 April 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
18 March 2022 In progress. Scoping commenced

For further information on our processes and methods, please see our CHTE processes and methods manual